For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Tafamidis meglumine represents a genuine change. These innovative therapies protect the transthyretin protein, halting its harmful build-up and reducing the burden of the condition . Patients are now seeing improvements